Ryplazim to treat Deep Vein Thrombosis - $16+ Billion MarketPer Fred: Ryplazim Pipeline
§ “The TMP trial in Sweden is progressing and 5 patients have been dosed to date – the purpose of this trial is to confirm the dosing regime and formulation for external wound-healing indications including DFU. DFU remains a large and potentially very valuable longer-term opportunity – however, we have dug deeper into the wide of acute indications for Ryplazim and are prioritizing the clinical development of those such as deep vein thrombosis, complications with central venous catheters and stroke which we are now confident can be most quickly become commercial opportunities following the full licensure of Ryplazim for congenital deficiency and the appropriate regulatory approvals for these other acute indications.“ (some of the “low hanging fruit” they were speaking of)
https://www.thepharmaletter.com/article/thrombosis-market-significant-revenue-opportunity-morgan-stanley-report Thrombosis is the formation of a blood clot within a blood vessel resulting in the restriction of blood flow through the circulatory system, and remains the world's largest single cause of mortality, despite the fact that medication has been available for over 50 years to treat and prevent the condition. A report by analysts at Morgan Stanley forecasts the global market size for this indication to increase from $5.1 billion in 2002 to $16.2 billion in 2010, with 65% of this revenue growth expected to come from the US market.